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تواتر اخللل الوظيفي الكبييب يف األطفال املصابني مبرض بيتا ثالسيميا 
الكربى يف
ب�صمة عبد �ملعز علي و �أحمد حممد حممود
abstract: Objectives: This study investigated the frequency of glomerular dysfunction in children with beta 
thalassaemia major (β-TM) by using different markers and correlating them with serum ferritin and iron chelation 
therapy. Methods: The study, carried out between August 2011 and May 2012, included 100 patients with β-TM, 
in two groups. Group Ia (n = 62) received chelation therapy (deferoxamine). Group Ib (n = 38) received follow-
up care at the Pediatric Hematology Outpatient Clinic, Minia University Children’s Hospital, Egypt. Group II 
included 50 apparently healthy controls, age- and sex-matched to Group I. All patients underwent a thorough 
history-taking, clinical examination and laboratory investigations. Results: Compared to Group II, Groups Ia 
and Ib had significantly higher levels of cystatin C, serum creatinine and serum ferritin, and a higher albumin/
creatinine ratio in their urine, and a significantly lower estimated glomerular filtration rate (eGFR) and creatinine 
clearance (P <0.05). Moreover, Group Ιa had a significantly lower eGFR and creatinine clearance than Group 
Ib. Cystatin C had a highly significant strong negative correlation with eGFR and creatinine clearance and a 
significantly strong positive correlation with serum ferritin, and a higher sensitivity and specificity than serum 
creatinine and creatinine clearance for small changes in GFR. Conclusion: β-TM patients had a high frequency 
of glomerular dysfunction—possibly attributable to chronic anaemia, iron overload or chelation therapy. Periodic 
renal assessment is mandatory to detect renal complications. Cystatin C is a promising marker to monitor 
glomerular dysfunction, having a higher sensitivity and specificity than serum creatinine and creatinine clearance 
for small changes in GFR.
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امللخ�ص: الهدف: هدفت هذه �لدر��صة �إىل �لتحقق من وترية حدوث �خللل �لوظيفي �لكبيبي يف �الأطفال �لذين يعانون من بيتا ثال�صيميا �لكربى با�صتخد�م 
موؤ�رش�ت خمتلفة و ربطها مع ن�صبة �لفرييتي و�لعالج �مل�صتخدم يف عملية �إز�لة �حلديد من �جل�صم. الطرق: �صملت �لدر��صة و�لتي �أجريت بي �أغ�صط�س 2011 
ومايو 2012 مائة من �ملر�صى �لذين يعانون من بيتا ثال�صيميا, و ق�صمت �إيل جمموعتي. �ملجموعة �الأوىل �أ )عددها 62( وتاأخذ عقار ديفريوك�صامي الإز�لة 
�حلديد من �جل�صم �أما �ملجموعة �الأوىل ب )عددها 38( دون تناول ذلك �لعقار مع متابعة �لرعاية �ل�صحية يف �لعيادة �خلارجية الأمر��س �لدم يف م�صت�صفى 
جامعة �ملنيا لالأطفال, م�رش. �صملت �ملجموعة �لثانية 50 من �الأ�صحاء �ملتطابقي من حيث �لعمر و�جلن�س مع �ملجموعة �الأويل وخ�صع جميع �ملر�صى 
الأخذ تاريخ دقيق وفح�س �رشيري وخمتربي.  النتائج: �أثبتت �ملقارنة بي �ملجموعة �الأويل )�أ( و )ب( مع �ملجموعة �لثانية �أن �ملجموعة �الأوىل )�أ ( و )ب( 
كان بها م�صتويات �ل�صي�صتاتي �صي, و م�صتوى �لكرياتيني و �لفرييتي يف م�صل �لدم, ومعدل ن�صبة �لزالل/ �لكرياتيني يف �لبول �أعلى بكثري من �ملجموعة 
�لثانية , وكذلك معدل �لرت�صيح �لكبيبي وت�صفية �لكرياتيني �أقل ب�صكل د�ل �إح�صائيا. وعالوة على ذلك وجد �أن معدل �لرت�صيح وت�صفية �لكرياتيني كان �أقل 
يف �ملجموعة �الأوىل )�أ ( عنه يف �ملجموعة �الأوىل )ب( ب�صكل د�ل �إح�صائيا ووجدت عالقة قويه عك�صية د�له �إح�صائيا بي �ل�صي�صتاتي �صي و معدل �لرت�صيح 
�لكبيبي وت�صفية �لكرياتيني و عالقة �إيجابية قوية ب�صكل ملحوظ بي م�صتوى �ل�صي�صتاتي �صى و م�صتوى �لفرييتي فى �مل�صل. وكانت ح�صا�صية وخ�صو�صية 
�ل�صي�صتاتي �صى فى �لتنبوؤ بالتغري�ت �ل�صغرية يف معدل �لرت�صيح �لكبيبي �أعلى من �لكرياتيني يف م�صل �لدم وت�صفية �لكرياتيني. و�خلال�صة: �ن مر�صى 
بيتا ثال�صيميا لديهم وترية عالية من �خللل �لكبيبي وقد يعزى ذلك �إىل فقر �لدم �ملزمن و �حلديد �لز�ئد �أو �لعالج �مل�صتخدم يف عملية �إز�لة �حلديد الإ�ستنتاج: 
�إن �لتقييم �لدوري للكلى �إلز�مي للك�صف عن �مل�صاعفات �لكلوية. �ل�صي�صتاتي �صي هو عالمة و�عدة لر�صد �خللل �لكبيبي, حل�صا�صيته وخ�صو�صيته �لعاليه 
للتغيري�ت �لب�صيطة يف �لرت�صيح �لكبيبي مقارنة مبوؤ�رش�ت �لكرياتيني و وت�صفية �لكرياتيني يف م�صل �لدم.
مفتاح الكلمات: �خللل �لكبيبي؛ بيتا ثال�صيميا؛ �صي�صتاتي �صي؛ �لعالج الإز�لة �حلديد؛ م�رش.
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Advances in Knowledge
- Glomerular dysfunction in children with beta major thalassaemia (β-TM) may be subclinical and, as this dysfunction may not be 
detected by routine testing, the use of early markers is recommended.
Application to Patient Care
- In β-TM patients, a close follow-up of glomerular dysfunction is necessary as it is not a rare complication.
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Beta thalassaemia (β-TM) is an inherited haemoglobin disorder characterised by the failure of the patient to 
produce beta haemoglobin chains, usually resulting 
in severe anaemia in its homozygous and compound 
heterozygous forms. The use of regular and frequent 
blood transfusions in patients with β-TM major has 
improved patients’ life spans and quality of life, but 
can lead to chronic iron overload.1 Unlike other 
organs, it is unclear whether kidney damage results 
solely from intravascular haemolysis, chronic 
transfusion or as a complication of iron chelation 
therapy.2 Patients with β-TM are known to have 
severe cardiopulmonary and reticuloendothelial 
dysfunction, but renal involvement has received 
little attention.3
Cystatin C is a 122-amino acid non-glycosylated 
protein of low molecular weight (13 kilodaltons 
[kDa]) that inhibits cysteine proteases. It is filtered 
by glomeruli and followed by tubular reabsorption 
and degradation, resulting in the excretion of a 
minute amount of cystatin C in the urine. It is 
not secreted by the renal tubules or reabsorbed 
back into the serum. Therefore, its serum levels 
serve as an endogenous parameter of glomerular 
filtration rate (GFR).4 Due to its small size, cystatin 
C is freely filtered by the glomerulus, and is not 
secreted but is fully reabsorbed and broken down 
by the renal tubules. This means that the primary 
determinate of blood cystatin C levels is the rate at 
which it is filtered at the glomerulus, making it an 
excellent marker of GFR. A recent meta-analysis 
demonstrated that serum cystatin C is a better 
marker for GFR than serum creatinine.4
Therefore, this study aimed to investigate 
the frequency of glomerular dysfunction in 
children with β-TM by using different markers 
and correlating them with serum ferritin and iron 
chelation therapy.
Methods
This cross-sectional study included an experimental 
group (Group I) of 100 patients, 72 males (65.5%) 
and 28 females (34.5%) aged 8–16 years and 
recruited from August 2011 to May 2012. Exclusion 
criteria included a patient history suggestive of 
recurrent urinary tract infections; the presence of 
systemic diseases affecting the kidney; the presence 
of rheumatic heart, thyroid, hepatic diseases, or 
diabetes mellitus; the intake of trimethoprim, 
corticosteroids or cephalosporin in the past seven 
days; a history of nephrotoxic drug use, and a family 
history of hereditary renal diseases. The control 
group included 50 apparently healthy volunteers 
who were age- and sex-matched to those in 
Group I.
The patients with β-TM were divided into two 
groups. Group Ia (n = 62) received regular chelation 
therapy consisting of deferoxamine (DFO) in doses 
of 20–40 mg/Kg per day via subcutaneous pump 
infusions over 8–12 hours/night for five days a 
week. Group Ib (n = 38) did not receive chelation 
therapy. Those in Group Ib underwent regular 
follow-up in the Pediatric Hematology Outpatient’s 
Clinic of the University Children’s Hospital of Minia 
University, Egypt. Written consent was received 
from the patients’ caregivers after the approval of 
the study by the University’s Ethical Committee. 
Both groups underwent a through history-
taking and clinical examination. Morning fasting 
blood samples and urine specimens were collected 
and tested for different biochemical function 
profiles, including simple urine analysis,5 an 
evaluation of the albumin/creatinine (A/C) ratio in 
the urine using the National Kidney Foundation’s 
level recommendations as a reference (female <3.5 
mg/mmol, male <2.5 mg/mmol)6 and creatinine 
clearance.7 The estimated glomerular filtration rate 
(eGFR) was calculated using the Schwartz formula 
for children, where constants were 0.44 for children 
<2 years and 0.55 for children ≥2 years:
Renal dysfunction was defined as eGFR <90 ml/
min per 1.73 m2.8 A complete blood count (CBC) 
was done using a Sysmex Complete Blood Count 
Analyzer (Sysmex Corporation, Kobe, Hyogo, 
Japan) and serum ferritin (ug/dL) was done by 
enzyme-linked immunosorbent assay (ELISA) 
- The use of alternative chelation therapy may decrease the possibility of renal damage by deferoxamine.
- Increased awareness among patients and their parents about the benefits of compliance to chelation therapy is a necessity.
eGFR (ml/min per 1.73 m2) = height (cm) × 
constant/serum creatinine (mg/dL)
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(R&D Systems, Minneapolis, USA).9 Renal function 
tests include blood urea with a reference range 
of 3.0–6.0 mmol/L and serum creatinine with a 
reference value for females of 40–90 μmol/L and 
males of 50–100 μmol/L) by a creatinine-Jaffe 
enzymatic assay using a spectrophotometer.10 
Finally, serum cystatin C level was measured by a 
Quantikine® human cystatin C immunosorbent 
assay (ELISA) kit (R&D Systems) with a reference 
value of 0.80–0.90 mg/L.11,12
The data were coded and verified prior to 
data entry. The Statistical Package for the Social 
Sciences (SPSS), Version 13 (IBM, Corp., Chicago, 
Illinois, USA), was used for data entry and analysis. 
All numeric variables were expressed as mean ± 
standard deviation (SD). Comparison of different 
variables in various groups was done using the 
Student’s t-test and Mann-Whitney U test for normal 
and non-parametric variables, respectively. The chi-
squared test (χ2) was used to compare the frequency 
of qualitative variables among the different groups. 
Pearson’s and Spearman’s correlation tests were 
used for correlating parametric and non-parametric 
variables, respectively. Multiple regression analysis 
was also performed to determine the effect of 
various factors on a dependent variable. A P value 
of >0.05 was determined as non-significant while 
a P value of <0.05 was significant. A Z-test was 
used to compare proportions and correlations.13 
A receiver operating characteristic (ROC) analysis 
was done to determine the accuracy of serum 
cystatin C versus serum creatinine and creatinine 
clearance by plotting the sensitivity and specificity 
of the experimental and control groups.
Results 
In this study, the frequency of glomerular 
dysfunction in children with β-TM was investigated 
by using different markers and correlating them 
with serum ferritin and iron chelation therapy. A 
comparison of Groups Ιa and Ib in regards to clinical 
findings showed that Group Ia had a significantly 
higher frequency of blood transfusions than group 
Ιb (P = 0.02) [Table 1]. Concerning the laboratory 
parameters, Table 2 shows that Groups Ιa and Ib 
had statistically significant higher levels of serum 
cystatin C, serum creatinine and serum ferritin, and 
a higher albumin/creatinine (A/C) ratio of the urine 
than Group II where P <0.05. On the other hand, 
they had a significantly lower eGFR as determined 
by Schwartz and a lower creatinine clearance than 
Group II.
A comparison between Groups Ia and Ib 
demonstrated that Group Ιa had a significantly lower 
eGFR and creatinine clearance than Group Ib (P = 
0.004 for each). In regards to different correlations, 
there were statistically significant strong negative 
correlations between serum cystatin C with eGFR 
and creatinine clearance where r = -0.91, P = 0.001 
and r = -0.80, P = 0.005, respectively. Moreover, 
there was an insignificant negative weak correlation 
with the frequency of blood transfusions (r = -0.14, 
P = 0.3) and a significant positive correlation with 
duration of chelation therapy, serum ferritin and 
A/C ratio in the urine (r = 0.29, P = 0.04; r = 0.9, 
P = 0.001; r = 0.82, P = 0.0001, respectively) 
[Table 3].
A ROC test was done for serum cystatin C and 
serum creatinine in β-TM patients and control 
groups, and it was found that the area under the 
curve (AUC) for serum cystatin C was significantly 
higher than that for serum creatinine [Figure 1]. 
Moreover, serum cystatin C had higher sensitivity 
and specificity than serum creatinine (65% versus 
27% and 91% versus 79%) [Table 4]. Table 5 and 
Figure 2 show that the AUC for serum cystatin C 
was significantly higher than that for creatinine 
clearance and serum cystatin C had higher 
sensitivity and specificity than creatinine clearance 
Table 1: Comparison between beta thalassaemia major 
patient subgroups by clinical characteristics


















Gender, n (%) Male 40 (64.5) 24 (63.2) 0.5
Female 22 (35.5) 14 (36.8)
Age of onset of transfusion 
in months, mean ± SD
7.8 ± 3.2 8.7 ± 2.6 0.07
Frequency of blood 
transfusion per year, mean 
± SD
11.3 ± 1.9 9.4 ± 4.03 0.02*
Splenectomy, 
n (%)
Positive 6 (9.7) 3 (7.9) 0.3
Negative 56 (90.3) 35 (92.1)
SD = standard deviation; *Significant.
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(67% versus 63% and 93% versus 66%, respectively).
Discussion
In this study, it should be noted that less attention 
was paid to renal complications. Koliakos et al. 
and others have conducted investigations of 
renal involvement in adult β-TM patients.14,15 
The current study was designed to investigate 
glomerular dysfunction in children with β-TM by 
using different markers, including cystatin C, and 
to correlate those findings with serum ferritin and 
iron chelation therapy. The current study found 
that Group Ia had statistically significant higher 
frequencies of blood transfusion than Group Ib 
(P = 0.02) [Table 1], this was perhaps due to the 
potential ignorance of the Group Ib parents and 
their failure to comply with treatment.
Concerning laboratory data, the current study 
found that β-TM patients, whether receiving 
chelation therapy or not, had statistically significant 
higher levels of serum cystatin C, serum creatinine 
and serum ferritin than those in the control group. 
On the other hand, they had a significantly lower 
eGFR and creatinine clearance than the control 
group. This could be explained by the possibility 
that renal dysfunction in patients with β-TM was 
due to long-standing anaemia, chronic hypoxia 
and iron overload.14 In addition, the shortened life 
span of red blood cells with rapid iron turnover and 
DFO therapy may have proven nephrotoxic.15 These 
results were in agreement with the results obtained 
Table 2: Comparison between the beta thalassaemia major subgroups and the control group by laboratory findings
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SD = standard deviation; ; eGFR = estimated glomerular filtration rate; *Significant.
Figure 1: Receiver operating characteristic curve 
for serum cystatin C and creatinine among beta 
thalassaemia major patients and the control group.
Figure 2: Receiver operating characteristic curve for 
serum cystatin C and creatinine clearance among beta 
thalassaemia major patients and the control group.
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by Grundy et al.16 and Hamed and ElMelegy17 who 
reported higher serum levels of serum cystatin C 
and serum creatinine and lower levels creatinine 
clearance. In contrast to the current study’s findings, 
Koliakos et al. found normal serum creatinine and 
creatinine clearance in β-TM patients who received 
subcutaneous DFO treatment.14
Concerning the urinary findings, the current 
study found that Groups Ιa and Ιb had statistically 
significant higher ratios of A/C in the urine than 
the control group. This albuminurea was attributed 
mainly to the destruction of the glomerular 
filtration membrane which may be due to massive 
iron deposition in the tissues, resulting in an 
increase of free radical production via the Fenton 
reaction, leading to cell death by binding cell 
proteins and disturbing their production.18,19 In 
addition, albuminurea could result from prolonged 
hyperfiltration, prostaglandin secretion and chronic 
anaemia.20
A comparison between Groups Ia and Ib in 
regard to some laboratory data showed that Group 
Ia had a significantly lower eGFR and creatinine 
clearance than Group Ib. This might be due to the 
shortened red blood cell life span with rapid iron 
turnover and tissue deposition of excess iron and 
the deferoxamine (DFO) therapy that may have 
proven nephrotoxic.15 In addition, Group Ia had a 
higher frequency of blood transfusion than Group 
Ib, where each 1 ml of packed red cells increases the 
body’s iron load by 1 mg, resulting in iron overload. 
Concerning different correlations, the current 
study found that serum cystatin C had a statistically 
higher, significantly strong negative correlation 
with eGFR and creatinine clearance where r = -0.91, 
P = 0.001 and r = -0.80, P = 0.005, respectively [Table 
3]. Because its biological variation is low, serum 
cystatin C gives a good assessment of GFR changes 
during follow-up.21 Furthermore, cystatin C had 
a statistically higher, significantly strong positive 
correlation with ferritin where r = 0. 90 and P = 
0.001. This may be due to increased iron deposition 
coming from multiple life-long transfusions and 
enhanced iron absorption, resulting in secondary 
haemosiderosis with secondary renal dysfunction.22
Serum cystatin C had a statistically significant, 
fair positive correlation with A/C ratio in the 
urine where r = 0.82 and P = 0.001. This could be 
explained by the possibility that proteinuria and 
microalbuminuria could be related to prolonged 
glomerular hyperfiltration and glomerulosclerosis.23 
Also, serum cystatin C had a highly significant 
positive correlation with the duration of chelation 
therapy, where r = 0.29 and P = 0.04.
In the present study, serum cystatin C and 
creatinine values were measured as markers of 
GFR in β-TM patients and a control group and 
therefore a ROC test was done for serum cystatin C 
and serum creatinine to determine the accuracy of 
serum cystatin C versus serum creatinine by plotting 
the claimed sensitivity and specificity of the β-TM 
Table 3: Correlations between cystatin C and different 
parameters
Parameter r† P
Duration of chelation in months 0.29 0.04*
Frequency of transfusion per year -0.14 0.3
eGFR in ml/min per 1.73 m2 -0.91 0.001*
Creatinine clearance in ml/min -0.80 0.005*
Serum ferritin in ng/ml 0.9 0.001*
Albumin/creatinine ratio 0.82 0.001*
eGFR = estimated glomerular filtration rate.
*Significant; †Grades of r: 0.00–0.24 (weak or no association); 
0.25–0.49 (fair association); 0.50– 0.74 (moderate association); 
>0.75 (strong association).
Table 4: Diagnostic accuracy of reduced glomerular filtration 
rate from serum cystatine C and serum creatinine among beta 


























AUC = area under the curve; SD = standard deviation; CI = confidence interval.
Table 5: Diagnostic accuracy of reduced glomerular filtration 
rate from serum cystatine C and creatinine clearance among beta 


























AUC = area under the curve; SD = standard deviation; CI = confidence interval.
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and control patients. This test strongly suggested 
that serum cystatin C was indeed superior to serum 
creatinine for the detection of GFR as the AUC was 
0.85 ± 0.04 for cystatin C versus 0.73 ± 0.05 for serum 
creatinine with higher sensitivity and specificity 
(66% and 92% versus 64% and 75%) [Table 4 and 
Figure 1]. This finding was in agreement with the 
results obtained by Larsson et al., who stated that 
plasma cystatin C provided a better indication of 
changes of GFR than serum creatinine.24
Table 5 and Figure 2 show that the AUC for 
serum cystatin C was significantly higher than that 
for creatinine clearance (0.85 ± 0.04 versus 0.35 
±0.05) when comparing β-TM patients with the 
control group. Also, the sensitivity and specificity 
of serum cystatin C were higher than creatinine 
clearance (66% and 92% versus 26% and 75%, 
respectively). This finding was in agreement with the 
findings obtained by Finney et al., who demonstrated 
that, in contrast to creatinine clearance, serum 
cystatin C concentration was effectively constant 
by the first year of life, and remained constant 
throughout adulthood up to 50 years of age.25 They 
also suggested that serum cystatin C might offer a 
considerable advantage to paediatric nephrologists 
in the diagnosis of GFR due to its sensitivity in the 
detection and reduction of GFR.
Conclusion
This study has shown that β-TM patients have a 
high frequency of glomerular dysfunction. This can 
be attributed to chronic anaemia, iron overload and 
DFO toxicity. Periodic renal assessment of those 
patients is mandatory as they may be affected by 
hidden renal dysfunction. Cystatin C is a promising 
marker to assist in monitoring glomerular 
dysfunction for small changes in GFR with higher 
sensitivity and specificity than serum creatinine and 
creatinine clearance.
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